BR112021022758A2 - Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos - Google Patents

Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos

Info

Publication number
BR112021022758A2
BR112021022758A2 BR112021022758A BR112021022758A BR112021022758A2 BR 112021022758 A2 BR112021022758 A2 BR 112021022758A2 BR 112021022758 A BR112021022758 A BR 112021022758A BR 112021022758 A BR112021022758 A BR 112021022758A BR 112021022758 A2 BR112021022758 A2 BR 112021022758A2
Authority
BR
Brazil
Prior art keywords
isoindoline
oxo
compositions
methods
substituted
Prior art date
Application number
BR112021022758A
Other languages
English (en)
Inventor
Chin-Chun Lu
Frans Baculi
Gang Lu
Joshua Hansen
Katherine Northcote
A Lebrun Laurie
a nagy Mark
d correa Matthew
Sophie Peng
Sophie Perrin-Ninkovic
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112021022758A2 publication Critical patent/BR112021022758A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos. a presente invenção refere-se a compostos de 1-oxo-isoindolina-5-carboxamida tendo a seguinte estrutura de fórmula (i), em que r1, r2, r3, r4 e n são como definidos nesta invenção, as composições compreendendo uma quantidade eficaz de um composto de 1-oxo-isoindolina-5-carboxamida e métodos para o tratamento ou prevenção de distúrbios.
BR112021022758A 2019-05-31 2020-05-29 Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos BR112021022758A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
BR112021022758A2 true BR112021022758A2 (pt) 2022-03-22

Family

ID=73551319

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022758A BR112021022758A2 (pt) 2019-05-31 2020-05-29 Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos

Country Status (16)

Country Link
US (2) US11306101B2 (pt)
EP (1) EP3976595A4 (pt)
JP (2) JP7496838B2 (pt)
KR (1) KR20220016167A (pt)
CN (3) CN118724867A (pt)
AR (1) AR119057A1 (pt)
AU (1) AU2020282748A1 (pt)
BR (1) BR112021022758A2 (pt)
CA (1) CA3136753A1 (pt)
CL (1) CL2021003134A1 (pt)
CO (1) CO2021015624A2 (pt)
IL (1) IL288278A (pt)
MX (1) MX2021014350A (pt)
PE (1) PE20220569A1 (pt)
SG (1) SG11202112872YA (pt)
WO (1) WO2020243379A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014350A (es) 2019-05-31 2022-02-21 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
US20220387405A1 (en) * 2021-05-06 2022-12-08 Celgene Corporation Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide
JP2024521966A (ja) * 2021-06-08 2024-06-04 ハンチョウ グルビオ ファーマシューティカル カンパニー，リミティド イソインドリノン化合物およびその用途
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
IL315083A (en) 2022-03-17 2024-10-01 Gilead Sciences Inc The IKAROS family of zinc fingers degrades and uses them
WO2023244818A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2024120441A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ES2434946T3 (es) 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
ZA200901078B (en) * 2006-08-30 2010-06-30 Celgene Corp 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ES2426350T3 (es) 2006-08-30 2013-10-22 Celgene Corporation Compuestos de isoindolina sustituidos en 5
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
MX2021014350A (es) 2019-05-31 2022-02-21 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.

Also Published As

Publication number Publication date
CN114957212A (zh) 2022-08-30
JP7496838B2 (ja) 2024-06-07
CN114269729A (zh) 2022-04-01
CN114957212B (zh) 2024-05-24
WO2020243379A1 (en) 2020-12-03
JP2022534979A (ja) 2022-08-04
CO2021015624A2 (es) 2022-02-28
US20220213115A1 (en) 2022-07-07
US20200377512A1 (en) 2020-12-03
AR119057A1 (es) 2021-11-17
AU2020282748A1 (en) 2021-12-09
EP3976595A1 (en) 2022-04-06
IL288278A (en) 2022-01-01
SG11202112872YA (en) 2021-12-30
MX2021014350A (es) 2022-02-21
EP3976595A4 (en) 2023-01-04
CA3136753A1 (en) 2020-12-03
JP2024123001A (ja) 2024-09-10
TW202110819A (zh) 2021-03-16
CL2021003134A1 (es) 2022-07-01
US11306101B2 (en) 2022-04-19
CN118724867A (zh) 2024-10-01
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20

Similar Documents

Publication Publication Date Title
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
BR112015028879A2 (pt) derivados heterocíclicos
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112017012197A2 (pt) composto, composição herbicida, mistura herbicida e método para controlar o crescimento de vegetação indesejada
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
BR112022025933A2 (pt) Compostos de ligação ao cereblon, composições dos mesmos e métodos de tratamento com os mesmos
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112022001390A2 (pt) Inibidores de enzima
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
BR112023022298A2 (pt) Moduladores de trex1